| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2026―Jan―02 |
Medication errors and associated serious outcomes in COVID-19 antivirals: a real-world study based on FDA Adverse Event Reporting System database |
Xiaomo Xiong, Zhanghe Chen, Bingfang Yan |
| 2 |
[GO] |
2024―Jan―28 |
Determinants of COVID-19 vaccine-induced myocarditis |
Jessica Rose, Nicolas Hulscher, Peter A. McCullough |
| 3 |
[GO] |
2023―Mai―22 |
Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature |
Sara Eslait-Olaciregui, Kevin Llinás-Caballero, David Patiño-Manjarrés, Thomas Urbina-Ariza, Juan Fernando Cediel-Becerra, Camilo Alberto Domínguez-Domínguez |
| 4 |
[GO] |
2023―Mrz―17 |
Impact of risk communication on patient’s safety during the pandemic |
Heyde-Patricia Zuluaga-Arias, Mayada Alkhakany, Manal M. Younus, Houda Sefiani, Angela Caro-Rojas, Sameh Al-Zubiedi, Wafi F. Albalawi, Thamir M. Alshammari |
| 5 |
[GO] |
2022―Dez―15 |
A survey on self-medication for the prevention or treatment of COVID-19 and distrust in healthcare of veterans in a primary care setting in the United States |
Eva Amenta, Larissa Grigoryan, Laura Dillon, Casey Hines-Munson, John Van, Barbara Trautner |
| 6 |
[GO] |
2022―Sep―05 |
Safety surveillance and challenges in accelerated COVID-19 vaccine development |
Abimbola Cole, Peggy Webster, Denny Van Liew, Maribel Salas, Omar Aimer, Marina A. Malikova |
| 7 |
[GO] |
2022―Aug―25 |
Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge |
Annette Rudolph, Joseph Mitchell, Jim Barrett, Helena Sköld, Henric Taavola, Nils Erlanson, Carlos Melgarejo-González, Qun-Ying Yue |
| 8 |
[GO] |
2022―Aug―05 |
Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience |
Irene R. Fermont, Ayalah Livneh, Michel Benhamou |
| 9 |
[GO] |
2022―Jul―21 |
Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir? |
Nicole F. Clark, Andrew W. Taylor-Robinson, Kirsten Heimann |
| 10 |
[GO] |
2022―Mai―25 |
Prescription for COVID-19 by non-medical professionals during the pandemic in Colombia: a cross-sectional study |
Maria Jose Nino-Orrego, Daniela Baracaldo-Santamaría, Claudia Patricia Ortiz, Heyde Patricia Zuluaga, Sthefany Alejandra Cruz-Becerra, Franklin Soler, Andrés M. Pérez-Acosta, Daniel Ricardo Delgado, Carlos-Alberto Calderon-Ospina |
| 11 |
[GO] |
2022―Apr―21 |
Drug safety of frequently used drugs and substances for self-medication in COVID-19 |
Daniela Baracaldo-Santamaría, Santiago Pabón-Londoño, Luis Carlos Rojas-Rodriguez |
| 12 |
[GO] |
2022―Mrz―29 |
The response to the COVID-19 pandemic trusted in pharmacovigilance to diminish communication risk |
Gustavo A. Quintero |
| 13 |
[GO] |
2022―Feb―26 |
Self-medication and the ‘infodemic’ during mandatory preventive isolation due to the COVID-19 pandemic |
Andrés Gaviria-Mendoza, Danny Alberto Mejía-Mazo, Carolina Duarte-Blandón, Juan Daniel Castrillón-Spitia, Manuel Enrique Machado-Duque, Luis Fernando Valladales-Restrepo, Jorge Enrique Machado-Alba |
| 14 |
[GO] |
2021―Aug―26 |
Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data |
Levin Thomas, Sumit Raosaheb Birangal, Rajdeep Ray, Sonal Sekhar Miraj, Murali Munisamy, Muralidhar Varma, Chidananda Sanju S.V., Mithu Banerjee, Gautham G. Shenoy, Mahadev Rao |
| 15 |
[GO] |
2021―Mai―14 |
Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis |
Upinder Kaur, Sankha Shubhra Chakrabarti, Tejas K. Patel |
| 16 |
[GO] |
2021―Mrz―15 |
Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages |
Arduino A. Mangoni, Gian Luca Erre |
| 17 |
[GO] |
2021―Feb―21 |
Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19 |
Phyo K. Myint, Ben Carter, Fenella Barlow-Pay, Roxanna Short, Alice G. Einarsson, Eilidh Bruce, Kathryn McCarthy, Alessia Verduri, Jemima Collins, James Hesford, Frances Rickard, Emma Mitchell, Mark Holloway, Aine McGovern, Arturo Vilches-Moraga, Philip Braude, Lyndsay Pearce, Michael Stechman, Angeline Price, Terence J. Quinn, Enrico Clini, Susan Moug, Jonathan Hewitt |
| 18 |
[GO] |
2021―Feb―13 |
Systematic review of immunosuppressant guidelines in the COVID-19 pandemic |
Fenella Barlow-Pay, Thura Win Htut, Mina Khezrian, Phyo Kyaw Myint |
| 19 |
[GO] |
2020―Sep―16 |
Hydroxychloroquine and chloroquine for COVID-19: psychiatric aspects of patient safety considerations |
Partha Sarathi Biswas, Devosri Sen |
